Meta-analysis of NPC2-mediated cholesterol transport in human cancers as a prognostic biomarker with therapeutic implications.

Cell CycleSep 23, 2026 (epub)
Clinical ResearchOncology (Medical)Pathology (Anatomic & Clinical)

Francisco Cezar Aquino de Moraes, Luis Henrique Rios Moreira Rego, Emanuele Rocha da Silva et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the prognostic significance of NPC2 expression in tumor tissues from 2,097 cancer patients. The study found that elevated NPC2 expression was significantly associated with worse overall survival across various cancers, with a hazard ratio of 1.29. The analysis included patients with gastric cancer, hepatocellular carcinoma, and gliomas, indicating NPC2's potential as a prognostic biomarker.

Key findings

  • Elevated NPC2 expression correlated with worse overall survival across cancers (HR 1.29, 95% CI 1.10-1.52, p = 0.001).
  • In gastric cancer, the association was stronger (HR 1.37, 95% CI 1.18-1.60, p < 0.001).
  • The cohort included 756 patients with gastric cancer, 374 with hepatocellular carcinoma, and 967 with gliomas.

Why it matters

Understanding the role of NPC2 in cancer biology could help identify patients with more aggressive tumors, potentially guiding treatment decisions and improving patient management strategies.

Source

PubMed · PMID 42775549

Published in Cell Cycle. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.